Asset Details
Do you wish to reserve the book?
In Silico Discovery of a Novel Natural Product Targeting PI3Kα for the Treatment of Head and Neck Squamous Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In Silico Discovery of a Novel Natural Product Targeting PI3Kα for the Treatment of Head and Neck Squamous Cell Carcinoma
Do you wish to request the book?
In Silico Discovery of a Novel Natural Product Targeting PI3Kα for the Treatment of Head and Neck Squamous Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In Silico Discovery of a Novel Natural Product Targeting PI3Kα for the Treatment of Head and Neck Squamous Cell Carcinoma
2025
Overview
Head and neck squamous cell carcinoma (HNSCC) remains a major health burden, with abnormal activation of phosphatidylinositol 3-kinase alpha (PI3Kα) strongly implicated in its pathogenesis. Targeting PI3Kα represents a promising therapeutic strategy. In this study, we employed structure-based virtual screening to identify natural small-molecule inhibitors of PI3Kα. A total of 12,800 molecules were screened, and five compounds were selected for further evaluation based on binding affinity and interaction patterns. Pharmacokinetic properties were assessed using ADMET predictions, and molecular dynamics (MD) simulations were conducted to validate the binding stability. Among the candidates, Apigetrin demonstrated favorable ADMET properties, a high safety profile, and stable binding within the ATP-binding pocket of PI3Kα. These findings suggest that Apigetrin is a promising natural PI3Kα inhibitor with potential therapeutic relevance for HNSCC.
Publisher
MDPI AG,MDPI
Subject
Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Biological Products - chemistry
/ Biological Products - pharmacology
/ Biological Products - therapeutic use
/ Enzymes
/ Genes
/ Head and Neck Neoplasms - drug therapy
/ Humans
/ Kinases
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Mutation
/ Phosphatidylinositol 3-Kinases - chemistry
/ Phosphatidylinositol 3-Kinases - metabolism
/ Phosphoinositide-3 Kinase Inhibitors
/ Squamous Cell Carcinoma of Head and Neck - drug therapy
/ Surgery
/ Tumors
